Tagged as: biosimilars

Biosimilar Market Updates: Samsung Biologics, Celltrion, and Alvotech

Samsung Biologics’ third quarter report disclosed that it had suspended its research and development of its SAIT101, a biosimilar of Rituxan.  As we previously reported, the rituximab product was being developed through Archigen Biotech, a joint venture with AstraZeneca.  According to a report in Korea Biomedical Review, a Samsung Biologics…

Read More

Survey of U.S. Rheumatologists Suggests Acceptance of Biosimilars for Treatment of New Patients, but Reluctance to Switch Patients from Reference Products

The results of a survey of board-certified rheumatologists in the United States about their beliefs and knowledge regarding biosimilar products were recently published in the journal Rheumatology. The online survey was conducted in May 2019 and included 19 multiple-choice questions assessing respondents’ knowledge of concepts and terminology concerning biosimilars, availability…

Read More

Lotus and CKD Announce Biosimilar Collaboration

On September 19, 2020, Lotus Pharmaceutical Co., Ltd. (“Lotus”) and Chong Kun Dang Pharmaceutical Corp. (“CKD”) announced that they have entered into a commercialization agreement in connection with CKD’s biosimilar darbepoetin alfa, a second-generation epoetin indicated for the treatment of anemia associated with chronic renal failure.  According to Lotus’ press…

Read More

Coherus Neulasta biosimilar loses preferred status at Express Scripts

Last week it was announced that Coherus BioSciences’s pegfilgrastim biosimilar Udencya would be excluded from Express Scripts’s preferred formulary starting January 1, 2021. The pharmacy benefit manager’s preferred Neulasta biosimilars for next year are Mylan’s Fulphila and Sandoz’s Ziextenzo.

Read More

Vizient Looks to Biosimilars to Help Contain COVID-19 Drug Price Inflation

Last week, Vizient, a healthcare performance improvement company, released its Summer 2020 Drug Price Forecast.  In the forecast, Vizient reported on the role of COVID-19 in changing healthcare priorities and affecting spending.  Particularly, it advised its member health care groups to hedge against drug price inflation, which it estimated will…

Read More